Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ONO PHARMACEUTICAL : Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) (94.2KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/04/2012 | 04:15am CEST

June 4th, 2012

ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)

Bristol-Myers Squibb Company (hereinafter referred to as "BMS") announced the results from Phase 1 study in patients with non-small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC) to be published in New England Journal of Medicine (NEJM) and presented at 48th

Annual Meeting of the American Society of Clinical Oncology (ASCO), on June 2nd (US time).

ONO-4538/BMS-936558, a fully human anti-PD-1 antibody, is an investigational cancer immunotherapy generated under a research collaboration entered into in May 2005 between Ono Pharmaceutical Co., Ltd. (hereinafter referred to as "Ono") and Medarex, Inc. When Medarex, Inc. was acquired by BMS in

2009, it also granted BMS its rights to develop and commercialize the anti-PD-1 antibody in North America. Through the collaboration agreement entered into in September 2011 between Ono and BMS, Ono granted BMS exclusive rights to develop and commercialize ONO-4538/BMS-936558 in the rest of the world, except in Japan, Korea and Taiwan where Ono has retained all rights to develop and commercialize the compound.

BMS is conducting a Phase 2 study in RCC in North America and Europe, and plans to initiate registrational studies for anti-PD-1 this year in NSCLC and RCC, and late 2012, early 2013 for metastatic melanoma. On the other hand, Ono is conducting a Phase 2 study in metastatic melanoma in Japan, and plans to initiate clinical studies in RCC and NSCLC, taking account of the development status in United States and Europe.

Attached from the following page is the press release made by BMS for your information.

Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1

Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
09/20 ONO PHARMACEUTICAL : Opdivo® (Nivolumab) Intravenous Infusion Approved for Expan..
09/19 ONO PHARMACEUTICAL : Opdivo® (Nivolumab) Intravenous Infusion Approved for Expan..
09/14 ONO PHARMACEUTICAL : Array BioPharma Announces FDA Acceptance for Review of Bini..
09/13 ONO PHARMACEUTICAL : Phase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Co..
09/13 ONO PHARMACEUTICAL : Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Pre..
09/12 EISAI : Conclusion of development collaboration agreement for lenvima and opdivo..
09/12 ONO PHARMACEUTICAL : Opdivo Plus Yervoy Combination Demonstrated Superior Overal..
09/11 ONO PHARMACEUTICAL : Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Su..
09/11 ONO PHARMACEUTICAL : Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survi..
09/09 EISAI : Conclusion of Development Collaboration Agreement for Lenvima (Lenvatini..
More news
News from SeekingAlpha
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/02 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 2, 2017
05/31 Array out-licenses binimetinib and encorafenib to Ono Pharma for Japan and So..
05/10 BRISTOL-MYERS SQUIBB : A Deep Dive Finds Some Pearls
01/23 Bristol Catches A Break At Last
Financials ( JPY)
Sales 2018 251 B
EBIT 2018 -
Net income 2018 38 761 M
Finance 2018 134 B
Yield 2018 1,93%
P/E ratio 2018 33,22
P/E ratio 2019 26,90
EV / Sales 2018 5,15x
EV / Sales 2019 4,71x
Capitalization 1 425 B
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 2 673  JPY
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
Sector and Competitors